<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01984320</url>
  </required_header>
  <id_info>
    <org_study_id>92013</org_study_id>
    <nct_id>NCT01984320</nct_id>
  </id_info>
  <brief_title>Cabergoline and Coasting to Prevent OHSS</brief_title>
  <acronym>OHSS</acronym>
  <official_title>Combining Cabergoline and Coasting in Gonadotropin Releasing Hormone(GnRH)Agonist Protocol in Intracytoplasmic Sperm Injection (ICSI) to Prevent Ovarian Hyperstimulation Syndrome (OHSS): a Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The effectiveness of cabergoline to prevent moderate-severe OHSS to coasting.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To randomly compare three study groups under a high risk of developing OHSS to one of three
      arms of management, either coasting for 1 to 3 days or receiving cabergoline for 8 days or
      coasting for 1 day plus receiving cabergoline for 8 days in ICSI patients following the long
      luteal GnRH agonist protocol.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate and degree of OHSS (composite outcome)</measure>
    <time_frame>14 days</time_frame>
    <description>Symptoms of nausea, vomiting, shortness of breath, abdominal pain,abdominal distension. Ovarian size and fluid in douglas pouch by ultrasound. Haematocrit, total leucocytic count, creatinine and Estradiol level as biochemical markers. Early OHSS first 9 days after ovum pickup and late is after 9 days till 14 days (time of pregnancy test)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of oocytes</measure>
    <time_frame>1 day</time_frame>
    <description>Number of oocytes collected on the day of oocyte collection</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Metaphase II (MII) oocytes</measure>
    <time_frame>1 day</time_frame>
    <description>Number of MII oocytes collected on the day of oocyte collection</description>
  </other_outcome>
  <other_outcome>
    <measure>Fertilization rate</measure>
    <time_frame>2 days</time_frame>
    <description>Number of embryos that show signs of fertilization in each patient</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of embryos</measure>
    <time_frame>3 to 5 days</time_frame>
    <description>Number of embryos assessed for embryo transfer in each patient</description>
  </other_outcome>
  <other_outcome>
    <measure>Implantation rate</measure>
    <time_frame>5 weeks</time_frame>
    <description>the ratio of the number of gestational sacs to the number of embryos transferred</description>
  </other_outcome>
  <other_outcome>
    <measure>Chemical pregnancy rate</measure>
    <time_frame>14 days</time_frame>
    <description>The patients who have a positive quantitative Beta human chorionic gonadotrophin (BHCG) and do not continue their pregnancy with a drop in the result and start of menstruation</description>
  </other_outcome>
  <other_outcome>
    <measure>Clinical pregnancy rate</measure>
    <time_frame>28 days</time_frame>
    <description>patients who show an intra-uterine gestational sac with positive fetal pulsations on ultrasound 14 days after their pregnancy test</description>
  </other_outcome>
  <other_outcome>
    <measure>Early miscarriage rate</measure>
    <time_frame>12 weeks</time_frame>
    <description>pregnancy loss in the first 12 weeks of gestation</description>
  </other_outcome>
  <other_outcome>
    <measure>Ongoing pregnancy rate</measure>
    <time_frame>12 weeks</time_frame>
    <description>pregnancies going beyond 12 weeks of gestation</description>
  </other_outcome>
  <other_outcome>
    <measure>Live birth rate</measure>
    <time_frame>40 weeks</time_frame>
    <description>live births occuring</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">300</enrollment>
  <condition>OHSS</condition>
  <arm_group>
    <arm_group_label>Coasting</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In their ICSI cycle patients will continue their agonist treatment while stopping the human menopausal gonadotropin (hMG) injections for 1 to 3 days until drop of estradiol to a safe level to prevent OHSS. Early OHSS is assessed at day of embryo transfer and 7 days after this date. Late OHSS is assessed 14 days after embryo transfer.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cabergoline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In their ICSI cycle patients will take 0.25 mg of cabergoline daily for 8 days from HCG triggering day to prevent OHSS. Early OHSS is assessed at day of embryo transfer and 7 days after this date. Late OHSS is assessed 14 days after embryo transfer.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Coasting and Cabergoline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In their ICSI cycle patients will continue their agonist treatment while stopping the human menopausal gonadotropin (hMG) injections for 1 day plus receiving 0.25 mg of cabergoline daily for 8 days from HCG triggering day to prevent OHSS. Early OHSS is assessed at day of embryo transfer and 7 days after this date. Late OHSS is assessed 14 days after embryo transfer.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ICSI</intervention_name>
    <description>Long luteal GnRH agonist protocol: patients will receive GnRH agonist from day 21 of the previous cycle of stimulation and then on day 3 of the stimulation cycle they will start hMG injections with 225 IU/day. Folliculometry will start on day 6 stimulation by vaginal ultrasound. Estradiol levels will be measured on day 8, 10 and 12 of stimulation if appropriate. According to ultrasound and estradiol level patients will be randomized to either one of the study arms. When ready final triggering will be done by human chorionic gonadotropin (10000 IU) and oocyte collection is done at 36 hour from triggering. Embryo transfer is then done 3 days afterwards with ultrasound guidance.</description>
    <arm_group_label>Coasting</arm_group_label>
    <arm_group_label>Cabergoline</arm_group_label>
    <arm_group_label>Coasting and Cabergoline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age &lt;or= 35, BMI &lt;or= 30

          2. Long protocol GnRH agonist cycles

          3. Estradiol level on day of HCG &gt;or= 3500 pg/ml

          4. Retrieving more than 15 oocytes

        Exclusion Criteria:

          1. Male factor

          2. Uterine factor
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamed Roushdy, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>IVF centre, Obstetrics and Gynaecology Department, Cairo University Hospitals (Kasr EL Aini)</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Esinler I, Bozdag G, Karakocsokmensuer L. Preventing ovarian hyperstimulation syndrome: cabergoline versus coasting. Arch Gynecol Obstet. 2013 Nov;288(5):1159-63. doi: 10.1007/s00404-013-2875-z. Epub 2013 May 16.</citation>
    <PMID>23677417</PMID>
  </reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 31, 2013</study_first_submitted>
  <study_first_submitted_qc>November 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 14, 2013</study_first_posted>
  <last_update_submitted>August 11, 2017</last_update_submitted>
  <last_update_submitted_qc>August 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Yasmin Ahmed Bassiouny</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>OHSS</keyword>
  <keyword>ICSI</keyword>
  <keyword>Coasting</keyword>
  <keyword>Cabergoline</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Hyperstimulation Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cabergoline</mesh_term>
    <mesh_term>Menotropins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

